The Road to Personalized Therapies: Lessons Learned From Angelman Syndrome.
Gene therapies for Angelman syndrome are coming, but only if behavior analysts supply sharp phenotype maps and sensitive outcome measures.
01Research in Context
What this study did
Duis (2022) wrote a story-style review about Angelman syndrome.
She summed up what scientists know about the genes, the behaviors, and the new drugs heading to human trials.
No new data were collected; she stitched together findings from many labs.
What they found
The field is moving from basic care to gene-directed therapies.
Success will hinge on clear maps of each person’s exact traits and on strong yardsticks to measure change.
How this fits with other research
Symons (2022) tells the same 2022 story, confirming the drug pipeline is real.
Heald et al. (2021) add a twist: kids without the big deletion work harder for social praise. Jessica flags this as a reason to split trial groups by genotype.
Petkova et al. (2022) give a concrete yardstick—automated gait scores—showing one biomarker ready for trials today.
Mertz et al. (2014) tracked the same kids for 12 years and saw slow language gains, easing fears that older participants can’t improve.
Why it matters
You may soon see clients enrolled in gene therapy trials. Use genotype-specific reinforcers, track gait and language with the new tools, and share baseline data so scientists can spot true drug effects.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Add gait speed and social-reinforcer preference tests to your intake battery.
02At a glance
03Original abstract
Angelman syndrome (AS) is a neurogenetic disorder characterized by delays including a severe expressive language delay, motor concerns, ataxia, epilepsy, sleep disturbances, gastrointestinal problems, and characteristic behaviors, including a happy demeanor, hyperactivity, and excitability. The syndrome is one of the first neurodevelopmental disorders with a clear trajectory towards meaningful treatment with approximately 20 companies actively developing targeted therapeutics for AS. Herein, we highlight the historical context of the road to therapeutics and some of the challenges in the field with the potential to impact the success of clinical trials for Angelman syndrome and also have relevance of other neurogenetic developmental disabilities.
American journal on intellectual and developmental disabilities, 2022 · doi:10.1352/1944-7558-127.2.95